May. 20 at 8:39 PM
$BLTE
🚨🚨🚨
Rolling FDA NDA submission for tinlarebant in STGD1 initiated, Q2 2026 completion targeted
Completed Phase 3 DRAGON trial in adolescent STGD1 patients
DRAGON II Phase 2/3 trial enrollment completed with 73 subjects, including 15 Japanese
PHOENIX Phase 3 GA trial enrollment completed with 530 subjects
Total cash, cash equivalents, and U.S. treasuries
$798.6M as of March 31, 2026
Other income rose to
$5.7M in Q1 2026 from
$1.2M a year earlier
GAAP net loss increased to
$26.9M from
$14.3M year over year
Non-GAAP net loss rose to
$13.7M from
$7.6M year over year
Research and development expenses increased to
$15.7M from
$9.4M
Selling, general and administrative expenses grew to
$17.0M from
$6.1M
Cash and cash equivalents declined to
$276.4M from
$352.9M since December 31, 2025
